TLDRs:
- Oklo stock fell nearly 16% as investors focused on upcoming regulatory milestones.
- The company held over $2.5 billion in cash and marketable securities in March.
- Groves reactor awaits final approvals before fuel loading and achieving criticality.
- Investors remain focused on execution rather than Oklo’s strong liquidity position.
Oklo (NYSE: OKLO) shares suffered a sharp weekly decline as investors shifted their attention away from the company’s healthy balance sheet and toward the next major regulatory hurdle for its nuclear technology roadmap.
The stock ended Friday’s session at $41.11, marking a 15.8% weekly loss after touching an intraday low of $39.53, making it one of the weakest performers among publicly traded advanced nuclear companies.
The decline came even though Oklo continues to maintain one of the strongest cash positions in the emerging nuclear energy sector. Instead, market participants appeared increasingly focused on whether the company can successfully meet its planned July milestones for its Groves critical assembly project, a key step in demonstrating execution capability ahead of future commercial reactor deployment.
Investors Shift Toward Execution
Oklo’s selloff outpaced several peers in the nuclear industry over the same period. NuScale Power declined 14.6%, while the VanEck Uranium and Nuclear ETF fell 9.0%. Meanwhile, Constellation Energy, one of the largest operators of commercial nuclear plants in the United States, managed to post a modest weekly gain.
The divergence suggests investors are placing greater emphasis on development timelines for emerging reactor developers than for established power producers. While the broader nuclear sector experienced weakness, Oklo’s larger decline indicates markets are demanding tangible progress rather than simply rewarding companies with promising long-term technology.
The broader equity market also added pressure during the week. Both the S&P 500 and Nasdaq finished lower, reflecting a generally cautious risk environment that weighed on higher-growth technology and energy names.
Strong Liquidity Offers Stability
Despite the stock’s weakness, Oklo remains well-funded.
As of March 31, the company reported approximately $2.537 billion in cash and marketable securities. During the first quarter, operating cash usage totaled $17.9 million, while capital expenditures reached roughly $32.8 million, bringing total cash spending for the period to just over $50 million.
Although future expenses are expected to fluctuate as development advances, the current balance sheet suggests that liquidity is not an immediate concern for investors.
Much of the company’s financial strength stems from recent fundraising efforts. During the quarter, Oklo issued approximately 12.38 million new shares, raising about $1.182 billion in net proceeds.
In addition, management established a $1 billion at-the-market equity program in May, providing flexibility to access additional capital if needed. While the facility strengthens funding options, it also introduces the possibility of future shareholder dilution, something investors continue to monitor closely.
July Milestone Draws Attention
The primary catalyst now centers on the company’s Groves project.
Earlier this month, the U.S. Department of Energy completed the project’s final safety analysis review, clearing an important regulatory hurdle. Before operations can begin, however, Groves must still complete a readiness review, receive final startup authorization, undergo fuel loading, and ultimately achieve criticality.
Chief Executive Officer Jacob DeWitte recently said the project “now moves into the final phase before startup, including readiness review, fuel loading, and criticality.”
Although Groves is not designed to generate commercial electricity, achieving criticality would represent an important technical and regulatory achievement. The facility operates as a 100-watt zero-power critical assembly intended to support nuclear research and isotope production rather than commercial energy generation.
Successfully reaching this milestone would demonstrate Oklo’s ability to navigate the complex licensing and construction process required for advanced nuclear systems, even if it does not directly validate the commercial performance of its larger Aurora reactor design.
Market Awaits Regulatory Clarity
For now, investors appear less interested in Oklo’s cash reserves than in evidence that the company can execute on schedule.
Confirmation of the readiness review or final startup approval could help ease uncertainty surrounding the July timeline and potentially restore investor confidence after the recent selloff.
At the same time, several risks remain. Delays in regulatory approvals, fuel availability challenges, construction costs, future licensing requirements, or additional equity issuance could all influence sentiment over the coming months.
While Oklo’s substantial cash position provides financial flexibility to continue advancing its projects, recent trading suggests the market is valuing operational execution above balance-sheet strength. As the company approaches its next regulatory milestone, investors will be watching closely for confirmation that development remains on track and that the long-awaited transition from planning to operational progress is moving forward.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
